A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

To join this study, your doctor would first need to confirm that you have bladder cancer that has either spread or is too advanced to be removed by surgery. They would also need to check if your cancer has a specific genetic change called an 'FGFR3 alteration' using a sample from your tumor or blood. You would also need to be generally well enough to take part in a study, meaning you can manage your daily activities.

There are also some important reasons why you might *not* be able to join. For example, if you've already had other treatments for your advanced or spread bladder cancer, or if you have certain unresolved side effects from previous treatments. You might also not be able to participate if you have severe nerve problems, uncontrolled cancer in your brain, or certain eye conditions like problems with your cornea or retina.

If you decide to join this study, you would receive either the new medicine, vepugratinib, or a placebo, in combination with enfortumab vedotin and pembrolizumab. These medicines are given at regular intervals, likely through an infusion (drip). You would have regular appointments at the hospital or clinic for these treatments, as well as for check-ups, blood tests, and scans to see how you are doing and how the treatment is affecting your cancer. These appointments will help the doctors monitor your health and any side effects. Your participation in the study could last for up to about six years, including the treatment period and follow-up to see how you are doing long-term.